Novo Nordisk, once the undisputed leader in the weight loss drug market with Ozempic and Wegovy, is now facing intense competition from Eli Lilly’s Zepbound, which has surpassed it in both efficacy and market share. CEO Maziar Doustdar acknowledges the company’s early missteps in understa
Sign up to read the full summary
Free AI-powered recaps of every episode, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.
Guest
Maziar Doustdar
interview on The Journal.
Mentions
Books, people, and resources mentioned in this episode.
People
Companies
Products & Tools
Topics
Listen to This Episode
More from The Journal.
How Big Food Is Navigating the GLP-1 Era
The Cancer Vaccine That Could Save Moderna
Weight-Loss Drugs Are Gobbling Up Small Town Budgets
The Flu Shot Drama at the FDA
Fashion Mogul Says Working Moms Need to Stop Apologizing
The Epic Drama at Lululemon
Related episodes
From other shows on similar topics.
Ozempic for All?
The Daily
People are running their own experiments with GLP-1s — with stunning results
Apple News Today
What we got wrong about GLP-1s
Search Engine
Yosef Martin on Building BoxyCharm, Selling for $500M, and Starting Over
The Determined Society with Shawn French | Adversity & Mindset
Reshaping the GLP-1 Economy: A Breaking Consumer Study
We Fixed It, You're Welcome
Skinny and sad on GLP-1s
Today, Explained
Get summaries like this every morning.
Free AI-powered recaps of The Journal. and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.